Idebenone: Applications and pharmacology
Jun 25,2023
General description
Idebenone is a drug that was initially developed by Takeda Pharmaceutical Company for the treatment of Alzheimer's disease and other cognitive defects. This has been met with limited success. The Swiss company Santhera Pharmaceuticals has started to investigate it for the treatment of neuromuscular diseases. In 2010, early clinical trials for the treatment of Friedreich's ataxia and Duchenne muscular dystrophy have been completed. As of December 2013 the drug is not approved for these indications in North America or Europe. It is approved by the European Medicines Agency (EMA) for use in Leber's hereditary optic neuropathy (LHON) and was designated an orphan drug in 2007. Chemically, idebenone is an organic compound of the quinone family. It is also promoted commercially as a synthetic analog of coenzyme Q10 (CoQ10). Its appearance is as follows:
Figure 1 Appearance of Idebenone
Applications
Idebenone improved learning and memory in experiments with mice.[1] In humans, evaluation of Surrogate endpoints like electroretinography, auditory evoked potentials and visual analogue scales also suggested positive nootropic effects, but larger studies with hard endpoints are missing. Research on idebenone as a potential therapy of Alzheimer's disease have been inconsistent, but there may be a trend for a slight benefit.[2] In May 1998, the approval for this indication was cancelled in Japan due to the lack of proven effects. In some European countries, the drug is available for the treatment of individual patients in special cases.
Preliminary testing has been done in humans and found idebenone to be a safe treatment for Friedreich's ataxia (FA), exhibiting a positive effect on cardiac hypertrophy and neurological function. The latter was only significantly improved in young patients. In a different experiment, a one-year test on eight patients, idebenone reduced the rate of deterioration of cardiac function, but without halting the progression of ataxia.[3] The drug was approved for FA in Canada in 2008 under conditions including proof of efficacy in further clinical trials. However, on February 27, 2013, Health Canada announced that idebenone would be voluntarily recalled as of April 30, 2013 by its Canadian manufacturer, Santhera Pharmaceuticals, due to the failure of the drug to show efficacy in the further clinical trials that were conducted. In 2008, the European Medicines Agency (EMA) refused a marketing authorisation for this indication. As of 2013 the drug was not approved for FA in Europe nor in the US, where there is no approved treatment.
In addition, after experiments in mice and preliminary studies in humans, idebenone has entered Phase II clinical trials in 2005 and Phase III trials in 2009. Phase I and II clinical trials for the treatment of MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) and primary progressive multiple sclerosis are ongoing as of December 2013. Idebenone is claimed to have properties similar to CoQ10 in its antioxidant properties, and has therefore been used in anti-aging on the basis of free-radical theory. Clinical evidence for this use is missing. It has been used in topical applications to treat wrinkles.[4]
Pharmacology
In cellular and tissue models, idebenone acts as a transporter in the electron transport chain of mitochondria and thus increases the production of adenosine triphosphate (ATP) which is the main energy source for cells, and also inhibits lipoperoxide formation. Positive effects on the energy household of mitochondria has also been observed in animal models.[23] Clinical relevance of these findings has not been established. Idebenone is well absorbed from the gut but undergoes excessive first pass metabolism in the liver, so that less than 1% reach the circulation. This rate can be improved with special formulations (suspensions) of idebenone and by administering it together with fat food; but even taking these measures bioavailability still seems to be considerably less than 14% in humans. More than 99% of the circulating drug are bound to plasma proteins. Idebenone metabolites include glucuronides and sulfates, which are mainly (~80%) excreted via the urine.
References
[1]Liu, XJ; Wu, WT (1999). "Effects of ligustrazine, tanshinone II A, ubiquinone, and idebenone on mouse water maze performance". Zhongguo Yao Li Xue Bao. 20 (11): 987–90. PMID 11270979.
[2]Gutzmann, H; Kühl, KP; Hadler, D; Rapp, MA (2002). "Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study". Pharmacopsychiatry. 35 (1): 12–8. doi:10.1055/s-2002-19833. PMID 11819153.
[3]Buyse G, Mertens L, Di Salvo G, et al. (May 2003). "Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring". Neurology. 60 (10): 1679–81. doi:10.1212/01.wnl.0000068549.52812.0f. PMID 12771265. S2CID 36556782.
[4]McDaniel D, Neudecker B, Dinardo J, Lewis J, Maibach H (September 2005). "Clinical efficacy assessment in photodamaged skin of 0.5% and 1.0% idebenone". J Cosmet Dermatol. 4 (3): 167–73. doi:10.1111/j.1473-2165.2005.00305.x. PMID 17129261. S2CID 2394666.
- Related articles
- Related Qustion
- Idebenone: A Multifaceted Compound for Antioxidant Activity and Mitochondrial Function Jan 18, 2024
Idebenone acts as an electron carrier and enhances antioxidant defense mechanisms, protecting against mitochondrial dysfunction through multiple pathways. NQO1 activation is crucial for its activity.
- About Idebenone Aug 27, 2019
Idebenone is used for Alzheimer's disease, Huntington’s disease, liver disease, and heart disease. It is also used for a number of inherited disorders including a condition that causes vision loss (Leber’s hereditary optic neuropathy), mitochondrial encephalomyopathies (nerve and muscle disorders), a type of muscular dystrophy called Duchenne muscular dystrophy, and Friedreich's ataxia (a nervous system disorder that worsens over time, producing gait and speech problems, and eventually leading toward heart disease and diabetes).
Methylcobalamin, a form of vitamin B12, has shown promising therapeutic effects in treating various conditions.....
Jun 25,2023APIChondroitin sulfate-based composites have several potential biomedical applications due to their inherent properties such as biocompatibility, biodegradability, and ability to mimic the matrix.....
Jun 26,2023APIIdebenone
58186-27-9You may like
- Idebenone
-
- $0.00 / 1Kg/Bag
- 2024-08-27
- CAS:58186-27-9
- Min. Order: 100g
- Purity: 98.5%min HPLC
- Supply Ability: 100KGS
- Idebenone
-
- $0.00 / 1kg
- 2024-08-26
- CAS:58186-27-9
- Min. Order: 0.10000000149011612kg
- Purity: ≥99%
- Supply Ability: 20tons
- Idebenone
-
- $800.00/ kg
- 2024-08-26
- CAS:58186-27-9
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 500kg